Call for Applications: Join the NMD4C’s Basic Science Trainee Committee
We are excited to share an opportunity for Canadian neuromuscular trainees to help shape NMD4C’s basic science trainee strategy by joining the NMD4C Basic Science Trainee Committee (BSTC)! Committee members will represent the interests of neuromuscular trainees, provide strategic input on NMD4C trainee opportunities, organize events/workshops, and help build a supportive community while developing their own leadership skills and professional network. The BSTC Terms of Reference provides more information about the committee roles and responsibilities!
Available Positions: Chaired by Dr. Jean-Philippe Leduc-Gaudet, the committee offers leadership positions (co-chair and secretary) as well as general members. General members will contribute to discussions, participate in decision-making, and lead specific initiatives. We’re looking for trainees with a collaborative spirit, strong communication skills, and a commitment to advancing neuromuscular research training.
Applications for the BSTC are now closed.
For questions or additional information, please contact network manager Erin Beattie at
Read next...
NMD4C Hosts 3rd Annual Basic Research Summer School at uOttawa!
From June 8 to 10, 2026, we hosted the 3rd annual NMD4C Basic Research Summer School at the University of Ottawa. The program supported 28 neuromuscular research trainees (graduate students and postdoctoral fellows) from across Canada and focused on developing practical skills, strengthening core knowledge in neuromuscular research, and providing opportunities to present and discuss their work. Through a combination of tutorials, lectures, hands-on workshops in cutting-edge wet lab techniques, flash talks, and both structured and informal networking, participants engaged with faculty, exchanged ideas, and built connections across institutions and career stages.
New Publication from the NMD4C Clinical Trial Network Strengthens Trial Capacity in Canada
We are pleased to share a new publication from the NMD4C Clinical Trial Network led by Kerri Lynn Schellenberg, Homira Osman, Maria Masnata, Rhiannon Hicks, Corinne Kagan, Ana Stosic, Stacey Lintern, Erin Beattie, Drs. Hanns Lochmüller, Craig Campbell, and Jean K Mah. This work focuses on the implementation of a coordinated Canadian neuromuscular clinical trial network to enhance trial readiness, capacity, and access in rare disease research.
Canadian-Led Phase II Studies Advance Vamorolone Evidence in Duchenne Muscular Dystrophy
NMD4C investigators contributed to two phase II studies evaluating vamorolone in boys with Duchenne muscular dystrophy across early childhood and adolescence, demonstrating safety, favorable pharmacokinetics, and potential efficacy. Led by Dr. Jean Mah and conducted across Canadian clinical trial sites with national and industry collaborators, the findings supported Health Canada approval of vamorolone as the first treatment for DMD in Canada. Leaders from both the clinical and patient advocacy communities, including Defeat Duchenne Canada, highlighted the impact of collaboration among patients, families, clinicians, and researchers in advancing care and improving access to new therapies.